Stock TT5 XTACY THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Xtacy Therapeutics Corp. Deutsche Boerse AG

Equities

TT5

CA98423G1072

Delayed Deutsche Boerse AG
Other stock markets
 02:01:29 2024-07-03 EDT 		5-day change 1st Jan Change
0.0175 EUR -2.78% Intraday chart for Xtacy Therapeutics Corp. +2.94% +40.00%
05-29 Xtacy Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
04-17 Xtacy Therapeutics Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Xtacy Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
CI
Xtacy Therapeutics Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023
CI
Xtacy Therapeutics Corp. Reports Earnings Results for the Full Year Ended September 30, 2023
CI
Xtacy Therapeutics Corp. Expands MDMA Platform Pharmaceutical Grade Psychedelic Solutions to Solve Unmet Medical Needs
CI
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
CI
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
CI
Global Wellness Strategies Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022
CI
Global Wellness Strategies Inc. Reports Earnings Results for the Full Year Ended September 30, 2022
CI
Global Wellness Strategies Inc. Announces Formation of Wholly Owned Pharma Subsidiary Focused on Clinical Trials
CI
Global Wellness Strategies Effervescent Cannabis Products Approved to Launch GWS Achieves Major Milestone Partnering with Hempsana Holdings
CI
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022
CI
Global Wellness Strategies Inc. Signs Custom Manufacturing Agreement with Hempsana Holdings
CI
Global Wellness Strategies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022
CI
Global Wellness Strategies Inc. Announces Shanti Therapeutics Mdma Clinical Trial Update
CI
Global Wellness Strategies Inc. Announces Their Brand KaleidoMyco to Launch Their Proprietary Fizz Tablets
CI
Global Wellness Strategies Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021
CI
Global Wellness Strategies Inc. and iNGENü Sign Supply Agreement with PharmAla Biotech to Supply GMP MDMA
CI
Global Wellness Strategies Inc. Reports Earnings Results for the Full Year Ended September 30, 2021
CI
Global Wellness Strategies Inc. completed the acquisition of Shanti Therapeutics Pty Ltd from Cannvalate PTY LTD.
CI
Global Wellness Strategies Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XTCY Stock
  4. TT5 Stock
  5. News Xtacy Therapeutics Corp.
  6. Highlights